Empiric Pulsed Field Pulmonary Vein Isolation During Atrial Tachycardia Ablation in Adults With Congenital Heart Disease

Launched by BOSTON CHILDREN'S HOSPITAL · May 5, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new approach called pulsed field ablation (PFA) to treat a condition called atrial tachycardia (AT) in adult patients who have congenital heart disease (CHD). Atrial tachycardia is an irregular heartbeat that can cause symptoms like palpitations and fatigue. The trial will test how safe and effective this new method is for isolating specific areas of the heart (pulmonary veins) that may be contributing to these fast heart rhythms.

To be eligible for this trial, participants need to be at least 18 years old and have congenital heart disease, whether it's fully repaired or not. They must also have experienced episodes of sustained atrial tachycardia lasting more than 30 seconds. However, if a person has had a history of sustained atrial fibrillation (a different type of irregular heartbeat) or previous procedures to isolate the pulmonary veins, they won’t be able to participate. If selected, participants can expect to undergo a procedure using the new technique, and their health will be closely monitored to see how well it works and if there are any side effects. This trial is not yet recruiting patients, but it aims to better understand treatment options for those with CHD and heart rhythm problems.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (\>= 18 years of age) with repaired or unrepaired congenital heart disease and a history of sustained (\>30 seconds) AT
• Exclusion Criteria:
• • History of sustained AF and/or previous catheter or surgical pulmonary vein isolation.